Lupin’s arms sign licensing agreement with Neopharmed Gentili S.p.A

18 Dec 2025 Evaluate

Lupin’s subsidiaries -- Multicare Pharmaceuticals and MedQuimica have signed an exclusive licensing agreement with Neopharmed Gentili S.p.A, an Italian pharmaceutical company, for marketing and promotional rights for the Gastroenterology brand, Plasil (metoclopramide), in their respective markets.

This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets. Neopharmed will oversee product supply in the Philippines, ensuring quality and compliance with global standards. In Brazil, production will be shifted to Medquimica’s manufacturing facility.

Plasil is widely acknowledged for its efficacy in treating nausea, vomiting, and motility disorders that affect millions of patients.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2118.25 5.10 (0.24%)
18-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1745.35
Dr. Reddys Lab 1279.60
Cipla 1499.10
Zydus Lifesciences 913.85
Lupin 2118.25
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×